By Michael Erman NEW YORK, April 27 (Reuters) - Johnson & Johnson is using artificial intelligence to slash by half the time ...
The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal ...
Regulatory approval is a major milestone in the drug development process, but it is not the final chapter in the journey.
SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- In today’s life sciences industry, moving a drug ...
The tech giant’s new AI platform aims to make drug discovery faster and cleaner.
Hosted on MSN
MindRank in phase 3 trial with China’s first AI-assisted new drug, cutting R&D costs by 60%
The company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029 Hangzhou-based biotech start-up MindRank has progressed to Phase 3 clinical trials for its ...
The US Food and Drug Administration (FDA) on Monday announced it will pilot a new program it hopes will spur the development of novel drug development tools (DDTs) that do not fit within the agency’s ...
Wanted: a cheap, multipotent treatment for viral infections. Must be able to handle new or unfamiliar strains, or (even ...
The goal of this collaborative was to examine the contributing factors towards the failure of late-stage clinical product development and develop key considerations for stakeholders to improve the ...
When we treat cancer patients, their disease can overcome treatment through its innate capacity to adapt. This is at the ...
A new procedural document issued by the US Food and Drug Administration (FDA) instructs its staff on the best practices-known as Good Review Practices (GVPs)-used in the review of investigational new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results